TB Alliance: Community engagement virtual forum

On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

To register for the webinar, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TB Alliance

Published: Aug. 5, 2021, 11:46 p.m.

Last updated: Aug. 8, 2021, 10:49 p.m.

Print Share